Evidence map›Paper›PMID 33784195›Full record

ArticleJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics2021

Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman Primates.

Uttio Roy Chowdhury, Rachel A Kudgus, Bradley H Holman, Tommy A Rinkoski, Cheryl R Hann, Cindy K Bahler, Eric McCloud, Susan E Appt, Joel M Reid, Peter I Dosa and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. KThe Journal of pharmacology and experimental therapeutics · 2023
    Article
  3. Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023
    Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Uttio Roy ChowdhuryDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Rachel A KudgusDepartment of Oncology Research, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Bradley H HolmanDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Tommy A RinkoskiDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Cheryl R HannDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Cindy K BahlerDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Eric McCloudDepartment of Pathology, Section of Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Susan E ApptDepartment of Pathology, Section of Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Joel M ReidDepartment of Oncology Research, Mayo Clinic Rochester, Rochester, Minnesota, USA.
Peter I DosaDepartment of Medicinal Chemistry, Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota, USA.
Michael P FautschDepartment of Ophthalmology, Mayo Clinic Rochester, Rochester, Minnesota, USA.

Funding

Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Vervet Research Colony as a Biomedical ResourceP40OD010965 · OD · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Matthew Jorgensen · 2012 to 2026
$14.6M
Intraocular pressure regulation via ATP-sensitive potassium channelsR01EY021727 · NEI · MAYO CLINIC ROCHESTER · PI FAUTSCH, MICHAEL P. · 2011 to 2021
$4.1M
NCATS NIH HHS UL1 TR001420NEI NIH HHS R01 EY021727NIH HHS P40 OD010965
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Administration, OphthalmicAdministration, TopicalAnimalsAntihypertensive AgentsArea Under CurveAutopsyBlood PressureChlorocebus aethiopsCromakalimDogsDose-Response Relationship, DrugFemaleHalf-LifeIntraocular PressureKATP ChannelsModels, AnimalAntihypertensive AgentsCromakalimKATP ChannelsProdrugsCKLP1dogsIOPKATP channel openerslevcromakalimnonhuman primates

Identifiers

PMID33784195
PMCPMC8215408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.